YWHAQ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Theta), also known as 14-3-3 theta or 14-3-3τ, is a member of the highly conserved 14-3-3 family of adapter proteins that regulate over 2,000 client proteins through phosphorylation-dependent interactions[1][2]. The 14-3-3 family consists of seven isoforms (β, ε, γ, η, σ, θ, ζ) that play essential roles in signal transduction, cell cycle regulation, apoptosis, metabolism, and stress responses[3]. In the nervous system, 14-3-3 proteins have emerged as critical modulators of neurodegeneration, with particular relevance to Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis[4][5].
YWHAQ is a 245-amino acid protein with a molecular weight of approximately 28 kDa. The protein lacks intrinsic enzymatic activity and functions purely as an adapter/scaffold[1:1].
The 14-3-3 proteins share a highly conserved structure[2:1][6]:
14-3-3 proteins function as obligatory dimers, with each monomer capable of binding independent client proteins[2:2]:
YWHAQ binds to client proteins containing phosphorylated serine/threonine residues within specific motifs[1:2][7]:
| Client | Binding Site | Functional Outcome |
|---|---|---|
| BAD | Ser112, Ser136 | Inhibits pro-apoptotic function |
| BAX | Ser184 | Prevents mitochondrial translocation |
| RAF1 | Multiple sites | Modulates MAPK signaling |
| TRADD | Various | Regulates TNF signaling |
| LRRK2 | Multiple sites | Modulates kinase activity |
YWHAQ has emerged as a particularly important player in Parkinson's disease pathogenesis[4:1][11][12]:
Lewy Body Pathology
LRRK2 Interaction
Dopaminergic Neuron Survival
Parkin Regulation
In Alzheimer's disease, 14-3-3 proteins show complex involvement[5:1][13]:
Tau Pathology
Amyloid-β Signaling
Synaptic Dysfunction
14-3-3 proteins are implicated in ALS pathogenesis[14]:
14-3-3θ is a well-established biomarker in prion diseases[16]:
| Approach | Compound | Stage | Notes |
|---|---|---|---|
| Peptide inhibitors | R18 derivatives | Preclinical | Competes with client binding |
| Stabilizers | Fusicoccin | Preclinical | Stabilizes 14-3-3-client complexes |
| Dissociators | BV02 | Preclinical | Disrupts 14-3-3 interactions |
| Allosteric | Not identified | Early | Challenge: flat protein surface |
| Partner | Interaction Type | Disease Relevance |
|---|---|---|
| α-Synuclein | Direct binding | PD - Lewy body formation |
| LRRK2 | Kinase regulation | PD - pathogenic mutations |
| Parkin | E3 ligase regulation | PD - mitophagy |
| Tau | Phospho-dependent | AD - NFT formation |
| BAD | Pro-apoptotic sequestration | Cell survival |
| BAX | Mitochondrial apoptosis | Cell death |
| RAF1 | MAPK signaling | Signal transduction |
Aitken, 14-3-3 proteins: a historic overview (2006). Seminars in Cancer Biology. 2006. ↩︎ ↩︎ ↩︎
Gardino et al. Structural determinants of 14-3-3 client interactions (2009). Trends in Biochemical Sciences. 2009. ↩︎ ↩︎ ↩︎
Morrison, The 14-3-3 proteins (2009). Trends in Cell Biology. 2009. ↩︎
Wang et al. 14-3-3 proteins in Parkinson's disease (2014). Journal of Neurology, Neurosurgery & Psychiatry. 2014. ↩︎ ↩︎
Xing et al. 14-3-3 proteins in Alzheimer's disease (2020). Journal of Alzheimer's Disease. 2020. ↩︎ ↩︎
Obsilova et al. 14-3-3 proteins: a family of molecular hubs (2021). Trends in Biochemical Sciences. 2021. ↩︎
Yaffe et al. [Phosphopeptide recognition by 14-3-3 proteins (1997)](https://doi.org/10.1016/S0092-8674(00). Cell. 1997. ↩︎
Zhang et al. 14-3-3 and MAPK signaling (2010). Cellular Signalling. 2010. ↩︎
Luk et al. 14-3-3 in cell cycle control (2010). Seminars in Cell & Developmental Biology. 2010. ↩︎
Masters et al. 14-3-3-mediated apoptosis regulation (2010). Apoptosis. 2010. ↩︎
Dumitriu et al. 14-3-3θ and LRRK2 in PD (2016). Movement Disorders. 2016. ↩︎
Wong et al. 14-3-3 proteins in dopaminergic neurons (2015). Cell Death & Disease. 2015. ↩︎
Qureshi et al. 14-3-3 in tauopathies (2013). Journal of Neuropathology & Experimental Neurology. 2013. ↩︎
Brotherton et al. 14-3-3 and ALS pathogenesis (2019). Acta Neuropathologica. 2019. ↩︎
Zhang et al. 14-3-3 in Huntington's disease (2017). Human Molecular Genetics. 2017. ↩︎
Collins et al. Cerebrospinal fluid 14-3-3 in prion disease (2015). Lancet Neurology. 2015. ↩︎
Genetics of Parkinson's Disease Consortium, 14-3-3 genetic associations (2019). Nature Genetics. 2019. ↩︎
Che et al. Ywhaq knockout mouse phenotype (2011). Molecular and Cellular Biology. 2011. ↩︎
Zhou et al. 14-3-3 transgenic models of PD (2018). Neurobiology of Disease. 2018. ↩︎
Cao et al. Targeting 14-3-3 proteins for therapy (2021). Journal of Medicinal Chemistry. 2021. ↩︎
Jetton et al. 14-3-3 post-translational modifications (2019). Cellular and Molecular Life Sciences. 2019. ↩︎